SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

• DOI: 10.1038/s41467-022-31495-x
• Publication Date: 2022-06-29T13:05:16Z
• Authors: Jia Wei; Philippa C. Matthews; Nicole Stoesser; Ian Diamond; Ruth Studley; Emma Rourke; Duncan Cook; John I. Bell; John N. Newton; Jeremy Farrar; Alison Howarth; Brian D. Marsden; Sarah Hoosdally; E. Yvonne Jones; David I. Stuart; Derrick W. Crook; Tim E. A. Peto; A. Sarah Walker; David W. Eyre; Koen B. Pouwels; ; Tina Thomas; Daniel Ayoubkhani; Russell Black; Antonio Felton; Megan Crees; Joel Jones; Lina Lloyd; Esther Sutherland; Emma Pritchard; Karina-Doris Vihta; George Doherty; James Kavanagh; Kevin K. Chau; Stephanie B. Hatch; Daniel Ebner; Lucas Martins Fer...; Thomas Christott; Wanwisa Dejniratt...; Juthathip Mongkol...; Sarah Cameron; Phoebe Tamblin-Ho...; Magda Wolna; Rachael Brown; Richard Cornall; Gavin Screaton; Katrina Lythgoe; David Bonsall; Tanya Golubchik; Helen Fryer; Stuart Cox; Kevin Paddon; Tim James; Thomas House; Julie Robotham; Paul Birrell; Helena Jordan; Tim Sheppard; Graham Athey; Dan Moody; Leigh Curry; Pamela Brereton; Ian Jarvis; Anna Godsmark; George Morris; Bobby Mallick; Phil Eeles; Jodie Hay; Harper VanSteenhouse; Jessica Lee; Sean White; Tim Evans; Lisa Bloemberg; Katie Allison; Anouska Pandya; Sophie Davis; David I. Conway; Margaret MacLeod; Chris Cunningham
• Keywords: Antibody response; Herd Immunity

Abstract Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out in many settings, there is a need for evidence to underpin optimum deployment, aiming maximise global population immunity. We evaluate whether single vaccination individuals who have already been infected generates similar initial subsequent antibody responses two vaccinations those without prior infection. compared anti-spike IgG after ChAdOx1, BNT162b2, or mRNA-1273 vaccines the COVID-19 Infection Survey UK general population. In 100,849 adults median (50 (IQR: 37–63) years) receiving at least one vaccination, 13,404 (13.3%) had serological/PCR of Prior infection significantly boosted responses, producing higher peak levels and/or longer half-lives dose all three than vaccinations. infection, time above positivity threshold was >1 year first vaccination. Single-dose targeted previously may provide as good protection two-dose among previous